This web publication constitutes a notice for the purposes of regulation 42ZCZS of the Therapeutic Goods Regulations 1990 (the Regulations). In accordance with regulation 42ZCZS, this notice publishes:
- A decision made by a delegate of the Secretary pursuant to regulations 42ZCZR
- reasons for that final decision
- date of effect of the decision.
Final decision in relation to amygdalin and hydrocyanic acid
Note that the final decision for amygdalin and hydrocyanic acid is not published in this notice. This decision has been delayed for further consultation.
Final decision and reasons
We aim to provide documents in an accessible format. If you're having problems using this document, please contact medicines.scheduling@health.gov.au.
Contents
- Notice of final decisions to amend (or not amend) the current Poisons Standard
- Final decisions on proposed amendments referred to the Advisory Committee on Medicines Scheduling (ACMS #42, June 2023)
- Final decision in relation to bisacodyl
- Final decision in relation to olopatadine
- Final decisions on proposed amendments referred to the Advisory Committees on Medicines and Chemicals Scheduling in joint session (ACMS-ACCS #34, June 2023)
- Final decision in relation to ibotenic acid
- Amendments to the Poison Standard in relation to New Chemical Entities (NCEs)
- Nirsevimab
- Tislelizumab